CAVALLETTO, LUISA
 Distribuzione geografica
Continente #
NA - Nord America 4.713
EU - Europa 892
AS - Asia 672
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
AF - Africa 1
Totale 6.285
Nazione #
US - Stati Uniti d'America 4.710
CN - Cina 381
IT - Italia 274
SG - Singapore 257
FI - Finlandia 150
DE - Germania 128
SE - Svezia 93
UA - Ucraina 67
FR - Francia 50
GB - Regno Unito 42
RU - Federazione Russa 30
IE - Irlanda 17
NL - Olanda 16
IN - India 13
HK - Hong Kong 10
AL - Albania 6
JP - Giappone 5
RO - Romania 4
AT - Austria 3
CA - Canada 3
ES - Italia 3
AU - Australia 2
BG - Bulgaria 2
DK - Danimarca 2
EU - Europa 2
SI - Slovenia 2
TR - Turchia 2
BE - Belgio 1
BR - Brasile 1
IL - Israele 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
PT - Portogallo 1
PY - Paraguay 1
UY - Uruguay 1
VN - Vietnam 1
Totale 6.285
Città #
Fairfield 633
Jacksonville 441
Houston 404
Chandler 379
Woodbridge 375
Ashburn 284
Wilmington 281
Cambridge 250
Ann Arbor 209
Seattle 195
Singapore 194
Boardman 158
Princeton 151
Santa Clara 82
Medford 81
San Diego 74
Nanjing 73
Beijing 58
Helsinki 55
Des Moines 48
Roxbury 34
Nanchang 24
Guangzhou 23
Hebei 23
New York 22
Shenyang 21
Padova 19
Milan 18
Dublin 17
Hefei 17
Jinan 16
Changsha 15
Dearborn 13
Jiaxing 13
Naples 12
Dallas 11
Norwalk 11
Tianjin 11
Hong Kong 10
London 10
Redwood City 10
Pune 9
Bari 8
Kharkiv 8
Rome 8
Zhengzhou 8
Ancona 7
Bologna 7
Kunming 7
Cagliari 6
Ningbo 6
Nuremberg 6
Hirakata 5
Ogden 5
Aci Catena 4
Borås 4
Brugherio 4
Chiswick 4
Rockville 4
Shanghai 4
Turin 4
Venice 4
Wuhan 4
Auburn Hills 3
Bergamo 3
Bitonto 3
Catania 3
Detroit 3
Fabriano 3
Fremont 3
Gunzenhausen 3
Hangzhou 3
Kilburn 3
Moretta 3
Ponzano Veneto 3
Potenza 3
San Jose 3
Tirana 3
Tortorici 3
Trieste 3
Washington 3
Acton 2
Brescia 2
Carbonera 2
Conversano 2
Cornedo Vicentino 2
Faro Superiore 2
Fuzhou 2
Gualdo Tadino 2
Hanover 2
Harbin 2
Horia 2
Leeds 2
Legnaro 2
Los Angeles 2
Majadahonda 2
Mascalucia 2
Messina 2
Mestre 2
Orange 2
Totale 4.993
Nome #
LA CURA DEL PAZIENTE CON EPATITE C: dall'epidemiologia alla buona pratica clinica attraverso metodologie sperimentali e di laboratorio. 291
Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study 143
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. 116
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 114
Kinetic of virological response during PEG-IFNs in chronic hepatitis C. 113
Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma 108
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 107
Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color doppler. 107
Hepatitis C Virus Reinfection in Liver Transplant Patients: Evaluation of Liver Damage Progression with Echo-Color Doppler 104
Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. 103
Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C 101
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 101
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS 96
Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. 95
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. 95
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 93
Profiles of HCV core protein and viremia in chronic hepatitis C: Possible protective role of core antigen in liver damage 93
Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population 90
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 90
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 88
HEPATITIS C VIRUS SEROTYPES AND LIVER PATHOLOGY 87
Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. 87
Therapy of hepatitis C: re-treatment with alpha interferon. 86
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C 84
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 79
Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals 75
Alterazioni neurovascolari nell’epatite cronica C: uno studio caso-controllo 74
Monitoring SCCA-IgM complex predicts hcc development in cirrhotic patients 73
Human leucocyte interferon-alpha in the treatment of chronic hepatitis C 72
Validation of a new sonographic parameter (liver/kidney ratio of greys intensity of digital images) for diagnosis and quantification of liver steatosis 72
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 72
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 71
Prognostic value of liver and spleen stiffness in patients with fontan associated liver disease (Fald): A case series with histopathologic comparison 70
Espressione della serpina SCCA in cellule mononucleate di sangue periferico in pazienti con infezione cronica da HCV 66
Epidemiological and clinical profile of HCV Chronic carriers in the area of northern Italy 66
Heart rate variability parallels changes in psychiatric scales in interferon-treated patients with chronic hepatitis. 64
ESPRESSIONE DELLA SERPINA SCCA IN CELLULE MONONUCLEATE DI SANGUE PERIFERICO IN PAZIENTI CO INFEZIONE CRONICA DA HCV 63
RESPONSE TO RIBAVIRIN, TO INTERFERON AND TO A COMBINATION OF BOTH IN PATIENTS WITH CHRONIC HEPATITIS C AND ITS RELATION TO HCV GENOTYPES 62
Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. 61
COMPARISON OF THRICE WEEKLY VS DAILY HUMAN LEUCOCYTE INTERFERON-ALPHA THERAPY FOR CHRONIC HEPATITIS C. TVVH STUDY GROUP. 60
TIMING AND DOSE EFFECT OF ALPHA-INTERFERON ON EARLY VIRAL KINETICS IN CHRONIC HEPATITIS C 60
CHRONIC HEPATITIS C WITHOUT ANTIBODY TO C-100 60
Deregulation of Squamous Cell Carcinoma Antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C 59
Comparison of thrice weekly vs daily human leucocyte interferon-alfa therapy for chronic hepatitis C. 58
Non invasive diagnosis of liver fibrosis progression by a clinical and us-doppler predictive model during chronic HCV infection 58
RESPONSE TO RIBAVIRIN, TO INTERFERON AND TO A COMBINATION OF BOTH IN PATIENTS WITH CHRONIC HEPATITIS C AND ITS RELATION TO HCV GENOTYPES 58
SCCA EXPRESSION IN PBMCs IN PATIENTS WITH CHRONIC HEPATITIS C 58
Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. 58
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 56
METABOLIC SYNDROME INDUCES A MORE RAPID PROGRESSION OF FIBROSIS IN PRIMARY BILIARY CIRRHOSIS IN EARLY STAGE 54
Neurophysiological bases of IFN toxicity in the treatment of viral hepatitis: Psychiatric, cognitive changes and long-term electrophysiological correlates. 54
NEUROCYTOKYNES CHANGES INDUCING PEG-INTERFERON-ALPHA DEPRESSION: A RATIONAL APPROACH TO INCREASE ADHERENCE OF THERAPY IN CHRONIC HEPATITIS C 53
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 53
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 53
Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals 52
Changes in serum tryptophan during antiviral therapy with recombinant alfa-interferon in chronic hepatitis C 51
DOWNREGULATION OF SURFACE SQUAMOUS CELL CARCINOMA ANTIGEN EXPRESSION AND CD27+ MOLECULE ON B LYMPHOCYTES IN PATIENTS WITH CHRONIC HEPATITIS C 50
Standard therapy for chronic HCV infection 50
Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. 49
RETREATMENT OF CHRONIC HEPATITIS C (CHC) WITH SEQUENTIAL INTERFERON RIBAVIRIN COMBINATION (IFN-RIBA) THERAPY 49
ESTIMATE OF FIBROSIS PROGRESSION DURING CHRONIC HEPATITIS C (CHC) IN NORTH-EAST ITALY 48
Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma 48
KINETIC OF VIROLOGICAL RESPONSE DURING PEG-IFNS IN CHRONIC HEPATITIS C. 47
Terapia con Peg-interferone e ribavirina nell'epatite cronica C: costo-efficacia e farmacoutilizzazione nella comune pratica clinica 47
Role of transient elastography to stage fontan-associated liver disease (Fald) in adults with single ventricle congenital heart disease correction 47
THE EFFECT OF RE-TREATMENT WITH INTERFERON ALONE OR INTERFERN PLUS RIBAVIRIN ON HCV QUASISPECIES DIVERSIFICATION IN NONRESPONDER PATIENTS WITH CHRONIC HEPATITIS C 46
Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group 45
ESPRESSIONE DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E CELLULE B DELLA MEMORIA IN CORSO DI INFEZIONE DA VIRUS DELL’EPATITE C 45
Non-invasive diagnosis of liver fibrosis progression by a clinical and US-Doppler predictive model during chronic HCV infection 44
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS. 44
SIGNIFICANCE OF HEPATITIS C VIRAEMIA IN ASYMPTOMATIC ANTI-HCV CARRIERS 44
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C 43
The effect of interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C. 40
Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alfa. 40
PREDICTORS OF SVR IN PATIENTS WITH NAIVE CHRONIC HCV TREATED WITH PEG-IFN ALFA-2B VS. ALFA-2A + RIBAVIRIN: A HIERARCHICAL LINEAR REGRESSION ANALYSIS OF RETROSPECTIVE DATA FROM 6 CLINIC SITES. 39
Aspetti farmacoeconomici della terapia antivirale nell'epatite cronica C 38
PEGYLATED ALPHA INTERFERONS (PEG-IFNs) PERIPHERAL NEUROTOXICITY: PROSPECTIVE STUDY IN CHRONIC HEPATITIS C. 36
CLINICAL SIGNIFICANCE OF SERUM AND LIVER TISSUE SCCA IN CHRONIC HEPATITIS 36
L'osservatorio epidemiologico e clinico sulle epatopatie croniche: uno strumento di politica sanitaria. 35
Preventing interferon-induced depression in a sample of 44 chronic hepatitis C patients with risk factor for depression 35
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. 34
Studio epidemiologico e prospettico delle epatopatie croniche: un progetto pilota nelle province di Padova e Venezia 32
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group. 29
DIFFERENT RATES OF HCV QUASISPECIES DIVERSIFICATION IN ASYMPTOMATIC CARRIERS AND IN PATIENTS WITH CHRONIC HEPATITIS 29
THE COMBINATION TREATMENT WITH RIBAVIRIN AND NATURAL INTERFERON- ALPHA MAY IMPROVE LONG TERM RESPONSE IN CHRONIC HEPATITIS C 29
LATE REACTIVATION OF CHRONIC HEPATITIS C AFTER SUSTAINED BIOCHEMICAL RESPONSE TO INTERFERON THERAPY 28
EVIDENCE THAT DOSE AND DURATION OF INTERFERON ALPHA (IFNa) THERAPY AFFECT LONG-TERM RESPONSE IN CHRONIC HEPATITIS C 28
HEPATITIS C VIRUS (HCV) GENOTYPES AND CLINICAL COURSE OF ANTI-HCV POSITIVE CIRRHOSIS 28
Antiviral therapy may change natural history of hepatitis C: clinical and histological modifications in a coohort of naive and treated patients 28
THE LONG-TERM RESPONSE (LTR) TO INTERFERON-ALPHA (IFN-2a) IN CHRONIC HEPATITIS C IS INFLUENCED BY DOSE AND DURATION OF TREATMENT AND BY THE HCV SEROTYPE 27
EFFICACIA DI DIFFERENTI TIPI DI DOSAGGI DI ALPHA-INTERFERONE IN SOGGETTI CON EPATITE CRONICA DI TIPO C 27
HEPATITIS C: DIAGNOSIS AND THERAPY 26
Novel pharmacogenetic test for management of antiviral therapy in patients with chronic hepatitis C 26
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of data from European Centers. 26
PILOT STUDY ON THE EFFICACY OF INTRAVENOUS NATURAL BETA-INTERFERON THERAPY IN ITALIAN PATIENTS WITH CHRONIC HEPATITIS C AND RELATION TO THE HCV GENOTYPE 25
Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group. 24
IS SUSTAINED RESPONSE TO ?-INTERFERON IN CHRONIC HEPATITIS C REALLY MANTAINED AT LONG-TERM FOLLOW-UP ? 23
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 22
LA TERAPIA DELL’EPATITE CRONICA DA HCV 21
PROBABILITA’ DI REATTIVAZIONE DELL’EPATITE C DOPO TERAPIA CON ALFA-INTERFERONE IN SOGGETTI CON PERSISTENTE RISPOSTA BIOUMORALE 21
Totale 6.165
Categoria #
all - tutte 25.695
article - articoli 19.842
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 494
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.160
Totale 47.191


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020505 0 0 0 0 0 0 0 130 112 137 47 79
2020/2021800 29 68 41 54 28 108 21 71 127 88 85 80
2021/20221.005 13 165 86 93 35 70 39 94 58 30 113 209
2022/20231.003 223 79 20 85 183 123 19 63 114 25 60 9
2023/2024419 13 51 45 33 37 53 27 13 11 12 59 65
2024/2025715 7 118 91 67 274 46 61 51 0 0 0 0
Totale 6.311